Delineating the effect of sex hormone intake on immunity in cis and

2 trans women with HIV

1

7 8

- 3 Chloé Pasin^{1,2,3,*}, David Garcia Nuñez⁴, Katharina Kusejko^{1,2}, Anna Hachfeld⁵, Hélène
- Buvelot⁶, Matthias Cavassini⁷, Lauro Damonti^{5,8}, Christoph Fux⁹, Begoña Martinez de 4
- Tejada¹⁰, Julia Notter¹¹, Alexandra Trkola², Huldrych F. Günthard^{1,2}, Karoline Aebi-5
- Popp^{5,\$}, Roger D. Kouyos^{1,2,\$}, Irene A. Abela^{1,2,\$}, and the Swiss HIV Cohort Study 6
- 9 ¹ Department of Infectious Diseases and Hospital Epidemiology, University Hospital
- 10 Zurich, University of Zurich, Zurich, Switzerland.
- ² Institute of Medical Virology, University of Zurich, Zurich, Switzerland. 11
- 12 ³ Collegium Helveticum, Zurich, Switzerland.
- 13 ⁴ Center for Gender Variance, Department of Plastic, Reconstructive, Aesthetic and
- 14 Hand Surgery, University Hospital Basel, Basel, Switzerland.
- ⁵ Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland 15
- 16 ⁶ Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
- 17 ⁷ Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland
- 18 ⁸ Ente Ospedaliero Cantonale, Division of Infectious Diseases, Regional Hospital
- 19 Lugano, Lugano, Switzerland
- 20 ⁹ Department of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau,
- 21 Switzerland

- ¹⁰ Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva 22
- and Faculty of Medicine, Geneva, Switzerland 23
- 24 ¹¹ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St.
- 25 Gallen, St. Gallen, Switzerland
- 27 * Corresponding author: chloe.pasin@usz.ch
- \$ These authors contributed equally. 28

29 **Abstract** 30 Background: Although sex hormones are recognized to induce immune variations, little 31 is known on the effect of exogenous sex hormone intake on immune responses in cis and 32 trans women. Here, we aimed at quantifying how sex hormone intake affects HIV-1 33 immune markers in cis women (CW) and trans women (TW) with HIV. 34 Methods: We considered measurements of key HIV-1 immune markers (CD4, CD8, 35 lymphocyte counts, and CD4:CD8 ratio) from cis men (CM), CW, and TW enrolled in the 36 Swiss HIV Cohort Study. We modeled immune markers using linear mixed-effects models with an interaction between the variables "group" (CW, TW) and "with sex hormone 37 38 intake" (yes/no). We conducted serum proteomics measurements of 92 inflammation 39 markers on samples from 31 TW before and after sex hormone intake to assess the 40 inflammation environment. 41 Results: We included 54'141 measurements from 3'092 CW and 83 TW sampled

Results: We included 54'141 measurements from 3'092 CW and 83 TW sampled between 2015 and 2022, and 147'298 from 8'611 CM. Sex hormone intake was associated with significant distinct effects on CD4 and CD4:CD8 ratio between the different groups of women (p=0.0025 and 0.015). TW with sex hormone intake had significantly higher CD4 counts (median = 772 (1Q-3Q=520-1'006)) than without (median = 617 (1Q-3Q=426-892)). This increase was similar in magnitude to the difference in CD4 counts between CW and CM. None of the serum inflammation proteins showed significant concentration difference before and after sex hormone intake in TW.

42

43

44

45

46

47

48

49

50

51

Conclusion: This study highlights the need to consider the potential role of sex hormone intake in modulating the immune system among other biological and social factors, especially in TW in HIV.

Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Sex and gender differences in the immune response have been observed in many settings, and in general women mount more robust cellular and humoral immune responses to infection and vaccination compared to men (1-6). These differences are multifactorial and could be influenced by the immuno-modulatory effect of sex hormones (7-9), with oestrogens having a stimulating effect (10) while testosterone having a suppressive effect on immune function (11). Sex hormones have also shown a multilevel effect on chronic infections such as HIV-1 (12), where women have displayed lower viral loads (13-15) and higher CD4+ T cell counts (16, 17) than men following seroconversion, and higher levels of immune activation (18, 19). Women also tend to have a lower latent HIV-1 reservoir size (20-22) and oestrogens were found to inhibit HIV-1 transcription (23). Although sex hormones could play a role in HIV-1 acquisition risk (24), recent evidence suggest that hormonal contraception does not affect the risk of HIV-1 acquisition (25-28) or disease progression (29, 30). However, the effect of sex hormones intake on HIV-1 immune markers dynamics has been insufficiently explored. Additionally, most of the findings previously mentioned were obtained by studying cis women (CW) versus cis men ("cis" referring to people whose gender identify matches the one assigned at birth), or without specifying this information. Trans women (TW, referring to people who were recorded male at birth but do not identify with being a man) are disproportionally affected by HIV-1 (31, 32) and constitute a distinct epidemiologic group compared to men having sex with men and cis women (32-34). TW are still under-represented in HIV-1 research; therefore, little is known on the immune effect of sex hormone intake in TW and more generally on the effect of hormonal therapy taken by TW on HIV-1 suppression and longer-term health outcomes (35-38). Additionally, concerns on drug-drug interactions between antiretroviral treatment (ART) and sex hormones might limit hormone prescription in women with HIV-1 (39, 40). The aim of this study was to analyze sex hormone intake in CW and TW from the SHCS. and to delineate the effect of sex hormones on key HIV-1 markers in CW and TW with sex hormone intake or not. Furthermore, we aimed to characterize the potential immunomodulatory effect of sex hormones in TW by measuring inflammatory protein levels before and after sex hormone intake using a high-throughput proteomics assay.

Results

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Study population

Participants from the Swiss HIV Cohort Study (SHCS) attend biannual visits during which blood samples are drawn and the following laboratory measurements are realized: number of leucocytes, lymphocytes, CD3+, CD4+, and CD8+ T cells (cells/μL), HIV-1 viral load (copies/mL). We considered measurements realized after January 1st, 2015: from that date, the SHCS data contains systematic report of most comedications using the ATC codes nomenclature. We included in the analysis a total of 54'141 laboratory measurements between January 2015 and September 2022 from 954 CW younger than 40 vears-old (CW<40), 2'365 CW between 40 and 60 years-old (CW 40-60), 573 CW older than 60 years-old (CW>60), and 83 TW (Figure 1). As a comparison we also considered similarly selected 147'298 laboratory measurements from 8'611 cis men. As previously described (33), TW in the SHCS were more likely to be of Asian and Hispano-American ethnicity compared to CW and had overall similar education levels as CW (Table 1). A higher proportion of TW had ever taken sex hormones compared to CW (69.9% versus 18.9%). We observed the highest CD4+ T cell, CD8+ T cell, and lymphocyte counts in TW with sex hormone intake (median respectively 772 cells/μL, 822 cells/μL, and 2288 cells/μL), while the CD4:CD8 ratio was the lowest in TW without sex hormone intake (median 0.80) (Table 2, Figure 2, Supplementary Figure 1, 2). CW>60 with sex hormone intake had the lowest proportion (0.2%) of samples with detectable viral load (RNA > 50 copies/mL), and TW without sex hormone intake the highest (8.3%). Of note, only a small proportions of viral load measurements in TW without sex hormone intake were above 1'000 copies/mL (1.3%, Supplementary Table 1).

Diversity of sex hormone intake in women from the Swiss HIV Cohort Study

Using information contained in the ATC codes, we were able to further differentiate the type of sex hormones taken by women from the SHCS, as well as their route of administration (Table 3, Supplementary Figure 3). CW<40 mostly reported the use of systemic progestogens (35.1%) or combined oestrogens and progestogens (36.9%), in line with the use of hormonal contraception (HC). CW>60 mostly reported the use of local

oestrogens (63.2%) or systemic combined oestrogens and progestogens (21.1%), corresponding to the use of menopause hormone therapy (MHT). In the group of CW 40-60, we observed more heterogeneity, with reports of HC use (systemic combined oestrogens and progestogens, 38.4%, and systemic progestogens, 21.1%) but also MHT (systemic and local oestrogens, respectively 17.6% and 14.5%), reflecting the potential overlap of contraception with the need for managing symptoms during perimenopause. Finally, TW mostly reported the use of oestrogens (53.2%) or combined oestrogens and antiandrogens (32.9%). Our descriptive analysis highlighted the diversity of sex hormone intake in women from the SHCS and the complexity of the data when assessing and comparing different age groups.

Sex hormone intake is associated with distinct effects on immune markers in CW

and TW with HIV

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

We assessed the effects of sex hormone intake on immune markers by using linear mixed-effect models adjusted for potential confounders such as years since ART start, ethnicity, intravenous drug use, education level, and age (Figure 3, Supplementary Figure 4). We found significantly different effects of sex hormone intake on CD4 and CD4:CD8 ratio between the studied groups (CW<40, CW 40-60, CW>60, and TW) (interaction p^{CD4}=0.02, p^{ratio}=0.007). Interestingly, we found a significant increase of CD4 counts. CD4:CD8 ratio, and lymphocyte counts associated with sex hormone intake in TW (effect on the scaled outcomes = 0.19, 95% confidence interval [0.10,0.28] for CD4 counts, 0.08 [0.02,0.15] for CD4:CD8 ratio, and 0.15 [0.04,0.25] for lymphocytes counts). CD4 and lymphocyte counts displayed high correlation in TW (Pearson r=0.78, p<0.001, Supplementary Figure 5), suggesting that the increase in lymphocyte counts in TW with sex hormone intake was mostly due to the observed increase in CD4 counts. Chronic viral and bacterial infections and lifestyle factors such as smoking could have an impact on immune markers (41-43). We conducted sensitivity analyses adjusted on smoking status and co-infection with hepatitis C and/or syphilis and found consistent results on the effect of sex hormones on immune markers (Supplementary Figure 6). We

further investigated whether changes in immune markers could be linked to viral control,

adherence to ART, and/or mental health problems. Interestingly, sex hormone intake was

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

significantly correlated with undetectable or suppressed viral load in both CW and TW (chi square test p<0.001 for CW<40, CW>60, and TW, and p=0002 for CW 40-60, Supplementary Table 1), with better self-reported adherence in CW<40 (chi square test p<0001) and CW 40-60 (chi square test p<0.001), but with more depression in CW<40 (chi square test p=0.025). When adjusting for depression, self-reported adherence, and viral load, the increase of CD4 counts in TW upon sex hormone intake remained significant (effect on the scaled outcome = 0.14 [0.05,0.23], Supplementary Figure 7), suggesting that this increase cannot solely be explained by better adherence to treatment and control of the virus. We further investigated whether the effects of sex hormones on immune markers in CW and TW were comparable to the differences in immune marker levels between cis men and CW (Supplementary Figure 8). Interestingly, the size of the effect of sex hormones on CD4 counts in TW was very similar to the difference of CD4 counts in CW (without sex hormone intake) versus cis men (CM, effect on the scaled outcome = 0.19 [0.14,0.24]). However, the effect on CD8 counts and lymphocytes was different, suggesting that sex and gender differences in immune markers cannot fully be compared to the inferred effect of exogenous sex hormone intake in CW and TW. Considering the diversity of sex hormones taken by the population of women in the SHCS, we also investigated the effect of different type and route of hormones among the defined groups (Figure 4). Among TW taking sex hormones, we found trends for lower CD4, CD8, and lymphocyte counts in TW with combinations of oestrogens and antiandrogens versus TW taking oestrogens only (p^{CD4}=0.075, p^{CD8}=0.052, and p^{lymphocytes}=0.090). Among CW<40 taking sex hormones, we observed significantly lower CD8 and lymphocyte counts and higher CD4:CD8 ratio (p^{CD8}=0.050, p^{lymphocyte}=0.015, p^{ratio}=0.004 respectively) among those taking progestogens only versus those taking oestrogens and progestogens in combination. No evidence for inflammatory pathways activation upon sex hormone intake in TW

We further sought to identify whether sex hormone intake had an anti-inflammatory effect in TW (44). To do so, we assessed the effect of sex hormone intake on immunity in 31

TW (19 taking oestrogens only and 12 taking a combination of oestrogens and

antiandrogens) by undertaking a targeted proteomic analysis of individual soluble inflammation-associated proteins in two sequential samples: one taken up to 2 years before the start of sex hormone intake (median 176 days, 1Q-3Q = 58-240 days) and one taken between 1 and 18 months after the start of sex hormone intake (median 175 days, 1Q-3Q = 155-225 days). Using an unsupervised hierarchical clustering strategy, we found no distinct immune signature between the samples taken before and after sex hormone intake (Supplementary Figure 9). After adjustment for multiple testing, we found no significant differential protein concentration in TW before and after sex hormone intake (Supplementary Table 2). Only two proteins displayed significant changes when considering the p-value unadjusted for multiple testing, namely neurotrophin-3 (NT-3, p=0.019) and STAMBP (p=0.032), for which we observed a decreased concentration upon sex hormone intake (Supplementary Figure 10).

Discussion

176

177

178

179

180

181

182

183

184

185

186

187

188

- 190 We report here on the first large cohort study analyzing the impact of exogenous sex
- 191 hormone intake on the immune system in women with HIV. Our study explicitly included
- 192 TW in the analysis to gain insights into effects of sex hormone intake on the immune
- 193 system in a population often understudied in HIV-1 research.
- 194 Although rates of MHT intake in menopausal cis women were previously reported in the
- 195 SHCS (45), we were now able to extensively describe the diversity of sex hormones taken
- 196 by women in the SHCS. Notably, our analysis highlighted the complexity of the
- menopausal transition, during which the need of HC and MHT are likely to overlap.
- 198 Based on a number of studies partially attributing sex and gender differences in immunity
- to the role of sex hormones (1-5, 16), we investigated how exogenous sex hormone intake
- affect major HIV-1 immune markers. Observed differences of sex hormone intake on
- immune markers (CD4, CD4:CD8 ratio) in CW and TW could be due to differences in the
- 202 combination of hormones taken. Indeed, TW mostly reported intake of oestrogens and/or
- antiandrogens and CW mostly reported intake of oestrogens and/or progestogens,
- depending on their age. Additionally, within each group, we did observe significant (in
- 205 CW<40) or trends (in TW) of differential effects on HIV-1 markers by type of sex hormone.

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

Differences in dosing and mechanisms of actions of sex hormones on the immune system in CW and TW could also explain our results and should be further investigated. Our most robust result was the significant association between sex hormone intake and an increase in CD4 counts in TW. This increase was similar in magnitude to the difference of CD4 counts between CW (not taking sex hormones) and CM, but this similarity was not identified for the other markers (CD8, CD4:CD8 ratio, lymphocytes). In line with previous work (46-48), this highlights the complexity and variety of factors (chromosomal, hormonal, and social) playing a role in immune modulation. Additionally, we explored how factors such as adherence and mental health could play a role in our analyses. Indeed, it has been reported that sex hormone intake in TW can be associated with lower adherence to ART, driven by concerns of drug-drug interactions (38, 39, 49). However, access to gender-affirming hormone therapy in TW was also shown to be associated with overall better mental health (50-52), which is known to be a good predictor for adherence in people with HIV (53-56). In our analysis, we did not find any association in TW between sex hormone intake and self-reported adherence to ART or depression. Even after adjusting for these variables, we still found a significant increase in CD4 counts with sex hormone intake in TW, suggesting that other social and biological factors are potentially responsible for this increase. However, we did identify a correlation between depression and HC in CW<40, in line with previous reports (57-59). Although previous results showed that mental health was not associated with adherence to ART or viral suppression during menopausal transition (60), more studies are needed in CW and TW with HIV to investigate the interplay between sex hormone intake, mental health, and immunity. Using a high-throughput serum proteomics approach, we aimed at identifying the inflammatory pathways potentially modulated with sex hormone intake in TW. We could not identify any proteins with significant concentration change before and after sex hormone intake in TW after adjusting for multiple testing. This negative result could be due to our low sample size or to the timing of the sampling before and after the start of sex hormone intake. Indeed, a previous report found that inflammatory markers were only transiently modified in TW receiving oral oestrogens, with a return to baseline levels between 2 to 6 months after the start of oestrogens intake (61). As the samples retrieved

from our biobank were obtained with a median of around 6 months after the start of sex hormone intake, we cannot exclude that this time window was not allowing us to identify transient inflammatory changes happening earlier after the start of sex hormone intake. Although all our statistical analyses were adjusted for confounders and we conducted several sensitivity analyses, this study is observational by design, and it is therefore not possible to definitely conclude on the causality between sex hormone intake and increase of CD4+ T cell counts in TW. Our analysis did not include longitudinal modeling of immune trajectories, preventing us to draw final conclusions on the time between start of sex hormone intake and potential modulations of immune markers. However, measurements at more regular and specific timepoints would be required to address this question. Additionally, we only observed the total number of cells, and the cohort design does not include any phenotyping of cells, which is preventing us to conclude on the cell subtypes with increased population with sex hormone intake. In conclusion, our results present new insights on the effect of exogenous sex hormone intake on the immune system of cis and trans women with HIV and highlights the need to consider the potential role of sex hormones in modulating the immune system among other biological and social factors.

Methods

Swiss HIV Cohort Study

The Swiss HIV Cohort Study (SHCS) is a prospective multicenter cohort study enrolling people with HIV in Switzerland (62). The SHCS was approved by the local ethical committees of the participating centers, and written informed consent was obtained from all participants. Participants are followed-up biannually with data collection including behavioral information, drug intake, gynecological exam if applicable. Blood samples are systematically drawn at each visit for laboratory measurements and storage in a biobank. In the main analysis, we considered laboratory measurements from samples drawn in CW and TW after January 1st, 2015, when systemic report of most comedications taken by SHCS participants started. Reports include (since 2015) ATC codes, drug brand, dose, and route of administration for both antiretrovirals and co-medication. We excluded from the analysis laboratory measurements that were sampled when participants were not on

- ART, less than 3 months after the first start of ART intake, during pregnancies, and during
- 269 hormone intake as subsequent treatment for bacterial vaginosis or treatment for
- 270 endometriosis (as these conditions could themselves be associated with changes in
- immunity).

275

278

279

- 272 As a comparison we also considered laboratory measurements in 147'298 samples on
- 273 ART for at least 3 months from 8'611 cis men after January 1st, 2015.

Cis and trans women in the SHCS

- We identified 86 TW using criteria previously described (33), and 3'165 CW with at least
- one laboratory measurement after January 1st, 2015.

Sex hormone intake definition

- Sex hormone intake was assessed using the following ATC codes: G02BA03 (hormonal
- intrauterine contraceptive with progestogens), G02BB (contraceptive vaginal ring with
- 282 oestrogens and progestogens in combination), G03A (hormonal contraceptive for
- systemic use), G03C (oestrogens), G03D (progestogens), G03E (androgens and female
- sex hormone in combination), and G03F (progestogens and oestrogens in combination).
- For each ATC code, report of the start and end of the corresponding drug are indicated.
- 286 Sex hormone reports for each participant were obtained by combining different sex
- hormones when taken at the same time (Supplementary Figure 3), then classified by the
- 288 type (e.g., oestrogens, progestogens, oestrogens + antiandrogens) and route (e.g.,
- 289 systemic, local) of intake. For example, a participant's report with a simultaneous intake
- of a product with ATC code G03CA (transdermal, oestrogens) and another product with
- 291 ATC code G03AC (systemic, progestogens) will be classified as systemic oestrogens +
- 292 progestogens.
- 293 Measurements that were realized on blood samples drawn during the period of sex
- 294 hormone intake were labeled as "with sex hormone intake", others "without sex hormone
- 295 intake".

296

297

Smoking, depression, and adherence definition

Information on smoking, depression, and self-reported adherence to ART (obtained during bi-annual visits) were linked to laboratory measurements realized up to 6 months before the corresponding follow-up visit.

Proteomics measurements

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

We retrieved plasma samples from the SHCS biobank: we selected 31 TW for which plasma samples were available both before the first reported start of sex hormone intake (between one month and two years) and after it (between three months and two years). with no reported interruption between the start of intake and the plasma collection. Proteomics measurements were realized on the 62 retrieved samples using the Olink® Target 96 technology Inflammation panel (63), which enables high-throughput, multiplex immunoassays by measuring up to 92 proteins across 96 plasma samples simultaneously (Olink Bioscience AB, Uppsala, Sweden). Olink® Target 96 is based on the Proximity Extension Assay (PEA). Using oligonucleotide-labeled antibody probe pairs, PEA permits simultaneous assessment of multiple proteins, maintaining the precision of dual epitope ELISA without the loss of specificity of earlier generation multiplex assays. Signal production requires both recognition of DNA barcoding from sequence-specific oligonucleotides and dual recognition of correctly matched antibody pairs. The PEA assay reports fold change in log₂ (Normalized Protein eXpression [NPX]) units. The Inflammation panel informs on factors involved in cell differentiation and cytokinemediated signaling pathways.

Statistical analysis

Studied outcomes (CD4+ T cell count, CD8+ T cell count, CD4:CD8 ratio, and total lymphocyte count) were transformed using square-root transformation for the cell counts and log transformation for the ratio, and then scaled. Each outcome was then expressed using a linear mixed effect model with fixed effects for the adjustment variable and a random effect for the individuals to account for repeated measurements. The linear mixed effect model can be written as follows:

$$y_{ij} = \sum_{k=1}^{n} \beta_k x_{kij} + b_i + \varepsilon_{ij}$$

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

Where y_{ij} is the jth observation of participant i, x_k is the kth of n fixed effects (variable of adjustment) and β_k its corresponding coefficient, b_i is the participant-specific normally distributed random effect and ϵ_{ii} the normally distributed residual error. For the fixed effect, we included a "group" variable (CW<40, CW 40-60, CW>60, TW) and a variable "with sex hormone intake" (yes, no). We considered CW in different age groups due to the strong correlation between the type of sex hormones used and the age of CW (i.e., CW<40 mostly take hormonal contraception, CW>60 mostly take hormonal replacement therapy, while the hormones taken by CW 40-60 are more heterogeneous). We tested whether the sex hormone intake was associated to the outcome differentially in the respective groups by estimating an interaction between the group variable and the sex hormone intake variable. The reference category was CW 40-60, as this was the group with the biggest sample size. We assessed the significance of the interaction term using a likelihood ratio test (complete model with interaction term, reduced model without interaction term). We report the effect of sex hormone intake in the different groups on the scaled outcomes and p-value of the likelihood ratio test for the interaction term. To control for potential confounders, we adjusted the models on the following variables: age at time of sample (continuous with splines), ethnicity, education level, time since ART start (continuous with splines), use of intravenous drugs. In sensitivity analyses, we also adjusted for depression, smoking status at time of sampling, self-reported adherence (three categories: never missed, missed once a month, and missed more than once every two weeks) and viral load (three categories: below 50 copies/mL, 50-1'000 copies/mL and >1'000 copies/mL). Given the left-censored nature of the proteomics data, the analysis was conducted in two steps: we first pre-selected proteins of interest, by excluding those with a proportion of censored values among the 62 samples more than 75%, and a dispersion value (standard deviation divided by the mean value) less than 5%. We then tested for differences between pre and post sex hormone intake samples using paired t-tests. Paired t-tests in proteins with left-censored data were realized using the function cen paired from the NADA2 R package. These analyses were conducted on all samples, on the subset of samples in participants taking oestrogens only, and on the subset of samples in

- participants taking a combination of oestrogens and anti-androgens. Multiple testing was
- 359 corrected using the FDR method.

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

Figure 1: Flow chart of laboratory measurements selection and repartition in the different subgroups. N corresponds to the number of samples with lab measurements, n corresponds to the number of SHCS participants (one participant can have several samples with lab measurements included in the analysis and can contribute to both the no hormone intake and hormone intake groups). **Figure 2:** Distribution of CD4+ and CD8+ T cell counts in the different studied populations: CW aged 40 and younger (purple), CW 40-60 years-old (red), CW older than 60 yearsold (orange), TW (green) and cis men (CM, black). Dashed line corresponds to the median among all measurements (CD4=657 cells/μL, CD8=715 cells/μL). For display purposes, 34 measurements (CD4>2500 cells/μL) and 77 measurements (CD8>3500 cells/µL) were excluded from the plot. Individual data points are shown in addition in Supplementary Figure 2. Figure 3: Effect of sex hormone intake in CW<40 (purple), CW 40-60 (red), CW>60 (orange), and TW (green) on the scaled studied outcomes: CD4 counts, CD8 counts, CD4:CD8 ratio and lymphocytes counts. Models were adjusted for potential confounders such as years since first start of ART, ethnicity, intravenous drug use, education level, and age. Figure 4: Effect of different type and route of hormones on immune markers: in green, comparison of TW taking oestrogens + androgens versus oestrogens only; in purple, comparison of CW<40 taking progestogens versus oestrogens+progestogens; in orange, comparison of CW>60 taking local oestrogens versus systemic oestrogen+progestogens. Models were adjusted for potential confounders such as years since first start of ART, ethnicity, intravenous drug use, education level, and age.

Table 1: Description of the population of cis women (CW) and trans women (TW) for which samples were included in the analysis

	cw	TW	Overall	
Sample size	n=3092	n=83	n=3175	
Age in 2022:				
median (min,max)	53 (18,95)	45 (21,75)	53 (18,95)	
Ethnicity: n(%)				
White	1642 (53.1%)	36 (43.4%)	1678 (52.9%)	
Black	1103 (35.7%)	5 (6.0%)	1108 (34.9%)	
Hispano-american	104 (3.4%)	16 (19.3%)	120 (3.8%)	
Asian	227 (7.3%)	25 (30.1%)	252 (7.9%)	
Other/unknown	14 (0.5%)	1 (1.2%)	15 (0.5%)	
Missing	2 (0.1%)	0 (0%)	2 (0.1%)	
Education: n(%)				
Less than bachelor	2329 (75.3%)	63 (75.9%)	2392 (75.3%)	
Bachelor and more	635 (20.5%)	18 (21.7%)	653 (20.6%)	
Other/unknown	47 (1.5%)	2 (2.4%)	49 (1.5%)	
Missing	81 (2.6%)	0 (0%)	81 (2.6%)	
IVD use: n(%)				
No	2549 (82.4%)	80 (96.4%)	2629 (82.8%)	
Yes	518 (16.8%)	3 (3.6%)	521 (16.4%)	
Missing	25 (0.8%)	0 (0%)	25 (0.8%)	
Has taken sex hormones at				
least once since 2015: n(%)				
No	2509 (81.1%)	25 (30.1%)	2534 (79.8%)	
Yes	583 (18.9%)	58 (69.9%)	641 (20.2%)	

Table 2: Description of lab measurements (CD4, CD8, and lymphocyte counts, CD4:CD8 ratio, detectable viral load) from the samples included in the statistical analysis. For each marker the number of measurements available (N) is displayed.

	CW < 40		CW 40-60		CW > 60		TW		CM
Under sex hormone	No	Yes	No	Yes	No	Yes	No	Yes	
Total sample size (N)	9730	1308	32030	3279	5786	618	637	753	147298
Age at sample time:	36 (32,38)	35 (30,38)	51 (46,55)	51 (45,55)	66 (63,71)	67 (62,76)	45 (38,52)	42 (37,50)	52 (44,59)
CD4 (cells/uL) (N)	8118	1108	27395	2805	5006	509	532	631	124823
median (Q1,Q3)	649 (480,861)	715 (557,954)	672 (488,887)	720 (548,929)	663 (477,878)	720 (580,893)	617 (426,892)	772 (520,1006)	651 (480,851)
CD8 (cells/uL) (N)	8064	1103	27194	2793	5001	494	531	616	123685
median (Q1,Q3)	674 (507,899)	656 (489,880)	675 (491,913)	651 (468,882)	656 (459,900)	557 (387,866)	755 (583,975)	822 (609,1033)	732 (534,996)
CD4:CD8 ratio (N)	8064	1103	27190	2793	5001	494	531	616	123679
median (Q1,Q3)	1.00 (0.70,1.35)	1.16 (0.81,1.54)	1.01 (0.71,1.39)	1.14 (0.82,1.59)	1.03 (0.67,1.50)	1.25 (0.92,1.76)	0.84 (0.56,1.12)	0.94 (0.69,1.22)	0.89 (0.62,1.24)
Lymphocytes (cells/uL) (N)	7974	1096	26670	2663	4812	487	525	618	121563
median (Q1,Q3)	1873 (1500,2332)	1908 (1529,2398)	1900 (1500,2400)	1937 (1569,2400)	1900 (1476,2395)	1870 (1558,2364)	2082 (1700,2581)	2288 (1768,2866)	1949 (1548,2421)
HIV-1 VL (copies/mL) (N)	9586	1288	31270	3212	5689	612	612	745	144228
Detectable VL (>50): n(%)	698 (7.2%)	45 (3.4%)	1499 (4.7%)	92 (2.9%)	256 (4.4%)	1 (0.2%)	53 (8.3%)	12 (1.6%)	6078 (4.1%)

Table 3: Description of sex hormones intake reported by women in the SHCS. Sex hormone reports are defined as explained in the supplementary figure 3. Total number of sex hormone reports in each group are displayed (n).

		CW<40	CW 40-60	CW>60	TW
		n=390	n=620	n=76	n=158
	Systemic	13 (3.3%)	109 (17.6%)	8 (10.5%)	84 (53.2%)
Oestrogens	Local	8 (2.1%)	90 (14.5%)	48 (63.2%)	0
	Systemic & local	0	2 (0.3%)	2 (2.6%)	0
	Systemic	137 (35.1%)	131 (21.1%)	2 (2.6%)	4 (2.5%)
Progestogens	Local	55 (14.1%)	28 (4.5%)	0	0
	Systemic & local	3 (0.8%)	0	0	0
	Systemic	144 (36.9%)	238 (38.4%)	16 (21.1%)	2 (1.3%)
Oestrogens + Progestogens	Local	8 (2.1%)	3 (0.5%)	0	0
	Systemic & local	3 (0.8%)	7 (1.1%)	0	0
Antiandrogens	Systemic	0	1 (0.2%)	0	7 (4.4%)
Oestrogens + Antiandrogens	Systemic	17 (4.4%)	9 (1.5%)	0	52 (32.9%)
Oestrogens + Androgens	Systemic	0	2 (0.3%)	0	5 (3.2%)
Oestrogens + Antiandrogens + Androgens	Systemic	0	0	0	3 (1.9%)
Ostrogens + Progestogens + Antiandrogens	Systemic	2 (0.5%)	0	0	1 (0.6%)

Acknowledgments. We thank the participants of the SHCS, the physicians and study nurses for excellent patient care, and the SHCS data center for excellent data management.

Members of the Swiss HIV Cohort Study: Abela I, Aebi-Popp K, Anagnostopoulos A, Battegay M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF (President of the SHCS), Hachfeld A, Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Jackson-Perry D (patient representatives), Kahlert CR (Chairman of the Mother & Child Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Kusejko K (Head of Data Centre), Labhardt N, Leuzinger K, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nemeth J, Nicca D, Notter J, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Salazar-Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory Committee), Tarr P, Trkola A, Wandeler G, Weisser M, Yerly S.

Financial support. This work has been financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #201369), by SHCS project #882 and by the SHCS research foundation. The data were gathered by the 5 Swiss university hospitals, 2 cantonal hospitals, 15 affiliated hospitals, and 36 private physicians (listed at http://www.shcs.ch/180-health-care-providers). IAA is supported by a research grant of the Promedica Foundation. CP is supported by a Fellowship from the Collegium Helveticum.

Potential conflicts of interests.

IAA has received honoraria from MSD and Sanofi, a travel grant from Gilead Sciences, and a grant from the Promedica foundation. RDK has received research fundings from Gilead unrelated to this work. AH's institution has received travel grants, congress and advisory fees from MSD, Viiv and Gilead, unrelated to this work. KAP's institution has received travel grants and advisory fees from MSD, Gilead and ViiV healthcare unrelated to this work. HFG has received grants from the SNF; SHCS; Yvonne Jacob Foundation;

434

435

436

437

438

439

440

441

442

443

444445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

University of Zurich's Clinical Research Priority Program, viral disease; Zurich Primary HIV Infection; Systems.X; National Institutes of Health; Gilead Sciences; and Roche; and personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson and Novartis, for consultancy or DSMB membership and a travel grant from Gilead. Authors contribution. CP, RDK: conception and design of the study, analysis and interpretation of data, drafting and revision of the article. IAA: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revision of the article. KAP: acquisition of data, analysis and interpretation of data, drafting and revision of the article. All other co-authors: acquisition of data, drafting and revision of the article. Data availability. The individual level datasets generated or analyzed during the current study do not fulfill the requirements for open data access: 1) The SHCS informed consent states that sharing data outside the SHCS network is only permitted for specific studies on HIV infection and its complications, and to researchers who have signed an agreement detailing the use of the data and biological samples; and 2) the data is too dense and comprehensive to preserve patient privacy in persons living with HIV. According to the Swiss law, data cannot be shared if data subjects have not agreed or data is too sensitive to share. Investigators with a request for selected data should send a proposal to the respective SHCS address (www.shcs.ch/contact). The provision of data will be considered by the Scientific Board of the SHCS and the study team and is subject to Swiss legal and ethical regulations, and is outlined in a material and data transfer agreement.

- 460 1. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males:
- implications for vaccine efficacy. Current opinion in physiology. 2018;6:16-20.
- 462 2. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the
- Outcomes of Vaccination over the Life Course. Annual Review of Cell and Developmental
- 464 Biology. 2017;33(1):577-99.
- 465 3. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol.
- 466 2016;16(10):626-38.
- 467 4. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines.
- 468 Lancet Infect Dis. 2010;10(5):338-49.
- Lotter H, Altfeld M. Sex differences in immunity. Semin Immunopathol. 2019;41(2):133-
- 470 5.
- 471 6. Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol. 2014;35(3):97-104.
- 7. Taneja V. Sex Hormones Determine Immune Response. Front Immunol. 2018;9:1931.
- 473 8. Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front
- 474 Immunol. 2018;9:2279.
- 9. Ortona E, Pierdominici M, Rider V. Editorial: Sex Hormones and Gender Differences in
- 476 Immune Responses. Frontiers in Immunology. 2019;10(1076).
- 477 10. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev
- 478 Allergy Immunol. 2011;40(1):66-73.
- 479 11. Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiebaut R, Tibshirani RJ, Davis
- 480 MM. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in
- 481 the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869-74.
- 482 12. Rechtien A, Altfeld M. Sexual dimorphism in HIV-1 infection. Seminars in
- 483 Immunopathology. 2019;41(2):195-202.
- 484 13. Napravnik S, Poole C, Thomas JC, Eron JJ, Jr. Gender difference in HIV RNA levels: a
- 485 meta-analysis of published studies. J Acquir Immune Defic Syndr. 2002;31(1):11-9.
- 486 14. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois
- 487 ED, Feeney ME. Sex Differences in HIV RNA Level and CD4 Cell Percentage During Childhood.
- 488 Clinical Infectious Diseases. 2011;53(6):592-9.
- 489 15. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial
- 490 Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal
- 491 of Medicine. 2001;344(10):720-5.
- 492 16. Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis.
- 493 2014;209 Suppl 3:S86-92.
- 494 17. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS,
- Shafer RW, Robbins GK, Pollard RB, Team A. Effect of Baseline- and Treatment-Related Factors
- on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects:
- 497 Results From ACTG 384. JAIDS Journal of Acquired Immune Deficiency Syndromes.
- 498 2006;42(4):426-34.
- 499 18. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ,
- Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins
- 501 GK, Altfeld M. Sex differences in the Toll-like receptor-mediated response of plasmacytoid
- dendritic cells to HIV-1. Nat Med. 2009;15(8):955-9.
- 503 19. El-Badry E, Macharia G, Claiborne D, Brooks K, Dilernia DA, Goepfert P, Kilembe W,
- Allen S, Gilmour J, Hunter E. Better Viral Control despite Higher CD4+ T Cell Activation during

- Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol. Journal of
- 506 Virology. 2020;94(16):e00758-20.
- 507 20. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N,
- Bogojeska J, Fellay J, Roth V, Kok YL, Thorball CW, Borghesi A, Parbhoo S, Wieser M, Boni J,
- Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M,
- Kouyos RD, Gunthard HF, Metzner KJ, the Swiss HIV Cohort Study. Determinants of HIV-1
- reservoir size and long-term dynamics during suppressive ART. Nat Commun. 2019;10(1):3193.
- 512 21. Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A,
- 513 Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M,
- 514 Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG. Sex-Based Differences in
- 515 Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. The
- 516 Journal of Infectious Diseases. 2018;219(7):1084-94.
- 517 22. Gianella S, Rawlings SA, Dobrowolski C, Nakazawa M, Chaillon A, Strain M, Layman L,
- 518 Caballero G, Scully E, Scott B, Pacis C, Weber KM, Landay A, Anderson C, Karn J. Sex
- 519 Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging.
- 520 Clinical Infectious Diseases. 2022;75(1):73-80.
- 521 23. Das B, Dobrowolski C, Luttge B, Valadkhan S, Chomont N, Johnston R, Bacchetti P, Hoh
- R, Gandhi M, Deeks SG, Scully E, Karn J. Estrogen receptor-1 is a key regulator of HIV-1 latency
- 523 that imparts gender-specific restrictions on the latent reservoir. Proc Natl Acad Sci U S A.
- 524 2018;115(33):E7795-E804.
- 525 24. Scully EP. Sex Differences in HIV Infection. Current HIV/AIDS Reports. 2018;15(2):136-
- 526 46.
- 527 25. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-
- Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S,
- Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-
- Jones D, van de Wijgert JH, Stalter R, Low N. Hormonal contraception and the risk of HIV
- acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12(1):e1001778.
- 532 26. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk
- of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15(2):181-9.
- 534 27. Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal
- contraception and HIV acquisition among women: an updated systematic review. BMJ Sexual &
- 536 Reproductive Health. 2020;46(1):8-16.
- 537 28. Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D, Gichangi PB,
- Heller KB, Hofmeyr GJ, Justman J, Kasaro MP, Kiarie J, Louw C, Mastro TD, Morrison CS,
- Mugo NR, Nair G, Nanda K, Nhlabatsi Z, Onono M, Palanee-Phillips T, Pleaner M, Rees H,
- 540 Singata-Madliki M, Scoville CW, Selepe RAP, Shears K, Sibiya S, Smit J, Steyn PS, Stringer J,
- Taylor D, Thomas KK, Welch JD. HIV incidence among women using intramuscular depot
- medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for
- contraception: a randomised, multicentre, open-label trial. The Lancet. 2019;394(10195):303-13.
- 544 29. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV
- disease progression: a systematic review. AIDS. 2013;27(5):787-94.
- 546 30. Whiteman MK, Jeng G, Samarina A, Akatova N, Martirosyan M, Kissin DM, Curtis KM,
- Marchbanks PA, Hillis SD, Mandel MG, Jamieson DJ. Associations of hormonal contraceptive
- 548 use with measures of HIV disease progression and antiretroviral therapy effectiveness.
- 549 Contraception. 2016;93(1):17-24.

- 550 31. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden
- of HIV in transgender women: a systematic review and meta-analysis. The Lancet Infectious
- 552 Diseases. 2013;13(3):214-22.
- 553 32. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global Epidemiology of HIV Infection
- and Related Syndemics Affecting Transgender People. JAIDS Journal of Acquired Immune
- 555 Deficiency Syndromes. 2016;72.
- 556 33. Nguyen H, Hampel B, Garcia Nuñez D, Battegay M, Hachfeld A, Bernasconi E, Calmy A,
- Cavassini M, Vernazza P, Fellay J, Rudolph H, Huber M, Leuzinger K, Perreau M, Scherrer A,
- Ramette AN, Yerly S, Günthard HF, Kouyos RD, Kusejko K, the Swiss HIV Cohort Study.
- 559 Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an
- 560 Epidemiologically Distinct Risk Group. Clinical Infectious Diseases. 2021.
- 561 34. Stahlman S, Liestman B, Ketende S, Kouanda S, Ky-Zerbo O, Lougue M, Diouf D, Anato
- 562 S, Tchalla J, Bamba A, Drame FM, Ezouatchi R, Kouamé A, Baral SD. Characterizing the HIV
- risks and potential pathways to HIV infection among transgender women in Côte d'Ivoire, Togo
- and Burkina Faso. Journal of the International AIDS Society. 2016;19(3S2):20774.
- 565 35. Gianella S, Sonya Haw J, Blumenthal J, Sullivan B, Smith D. The Importance of Human
- 566 Immunodeficiency Virus Research for Transgender and Gender-Nonbinary Individuals. Clin
- 567 Infect Dis. 2018;66(9):1460-6.
- 568 36. Jaspal R, Kennedy L, Tariq S. Human Immunodeficiency Virus and Trans Women: A
- Literature Review. Transgend Health. 2018;3(1):239-50.
- 570 37. Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV
- treatment: a comprehensive review of the literature and recommendations for best practices. J Int
- 572 AIDS Soc. 2016;19(3 Suppl 2):20810.
- 573 38. Wansom T, Guadamuz TE, Vasan S. Transgender populations and HIV: unique risks,
- 574 challenges and opportunities. J Virus Erad. 2016;2(2):87-93.
- 575 39. Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, Lake JE.
- 576 Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing
- 577 Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns. LGBT
- 578 Health. 2017;4(5):371-5.
- 579 40. Murray MM, Jensen A, Cieslik T, Cohn SE. Potential risk of drug-drug interactions with
- hormonal contraceptives and antiretrovirals: prevalence in women living with HIV. Drugs Context.
- 581 2020;9.
- Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent Tobacco Smoking is Associated with
- Poor HIV Medical Outcomes Among HIV-Infected Individuals in New York. AIDS and Behavior.
- 584 2016;20(8):1722-9.
- 585 42. Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, Gandhi M,
- 586 Mocharnuk RS, Anastos K. Association of Cigarette Smoking With HIV Prognosis Among
- Women in the HAART Era: A Report From the Women's Interagency HIV Study. American
- 588 Journal of Public Health. 2006;96(6):1060-5.
- 589 43. Muccini C, Crowell TA, Pinyakorn S, Kroon E, Sacdalan C, Ananworanich J, Vasan S,
- 590 Phanuphak N, Colby DJ. Brief Report: Syphilis Incidence and Effect on Viral Load, CD4, and
- 591 CD4/CD8 Ratio in a Thai Cohort of Predominantly Men Who Have Sex With Men Living With
- 592 HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2021;86(2).
- 593 44. Giltay EJ, Fonk JCM, von Blomberg BME, Drexhage HA, Schalkwijk C, Gooren LJG. In
- 594 Vivo Effects of Sex Steroids on Lymphocyte Responsiveness and Immunoglobulin Levels in
- Humans. The Journal of Clinical Endocrinology & Metabolism. 2000;85(4):1648-57.


- 596 45. Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr Philip E, Darling K, Babouee Flury B,
- Polli C, Sultan-Beyer L, Abela IA, Aebi-Popp K, the Swiss HIV Cohort Study. Women with HIV
- 598 transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). HIV
- 599 Medicine. 2022;23(4):417-25.
- 600 46. Peckham H, Webb K, Rosser EC, Butler G, Ciurtin C. Gender-Diverse Inclusion in
- Immunological Research: Benefits to Science and Health. Front Med 2022;9:909789.
- 602 47. Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21-603 9.
- 604 48. Pulendran B. Systems vaccinology: Probing humanity's diverse immune systems with
 - vaccines. Proceedings of the National Academy of Sciences. 2014;111(34):12300.
 - 606 49. Lacombe-Duncan A, Bauer GR, Logie CH, Newman PA, Shokoohi M, Kay ES, Persad Y,
 - 607 O'Brien N, Kaida A, de Pokomandy A, Loutfy M. The HIV Care Cascade Among Transgender
 - Women with HIV in Canada: A Mixed-Methods Study. AIDS Patient Care and STDs.
 - 609 2019;33(7):308-22.
 - 50. Jäggi T, Jellestad L, Corbisiero S, Schaefer DJ, Jenewein J, Schneeberger A, Kuhn A,
 - 611 Garcia Nuñez D. Gender Minority Stress and Depressive Symptoms in Transitioned Swiss
 - Transpersons. BioMed Research International. 2018;2018:8639263.
 - 613 51. Baker KE, Wilson LM, Sharma R, Dukhanin V, McArthur K, Robinson KA. Hormone
 - Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review.
 - Journal of the Endocrine Society. 2021;5(4):bvab011.
 - 616 52. Hughto JMW, Gunn HA, Rood BA, Pantalone DW. Social and Medical Gender
 - Affirmation Experiences Are Inversely Associated with Mental Health Problems in a U.S. Non-
 - Probability Sample of Transgender Adults. Archives of Sexual Behavior. 2020;49(7):2635-47.
 - 619 53. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B,
 - 620 Bernasconi E, Rickenbach M, Günthard HF, Bucher HC, the Swiss HIV Cohort Study.
 - 621 Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to
 - Antiretroviral Therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency
 - 623 Syndromes. 2010;54(2).
 - 624 54. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV Infected
 - Patients: a Review. Current Psychiatry Reports. 2014;17(1):530.
 - 626 55. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and
 - 627 HIV/AIDS: the need for an integrated response. AIDS. 2019;33(9).
 - 628 56. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and Adherence to
 - Antiretroviral Therapy in Low-, Middle- and High-Income Countries: A Systematic Review and
 - Meta-Analysis. Current HIV/AIDS Reports. 2014;11(3):291-307.
 - 631 57. de Wit AE, Booij SH, Giltay EJ, Joffe H, Schoevers RA, Oldehinkel AJ. Association of
 - Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women.
 - 633 JAMA Psychiatry. 2020;77(1):52-9.
 - 634 58. Kulkarni J. Depression as a side effect of the contraceptive pill. Expert Opinion on Drug
 - 635 Safety. 2007;6(4):371-4.
 - 636 59. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal
 - 637 Contraception With Depression. JAMA Psychiatry. 2016;73(11):1154-62.
 - 638 60. Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr PE, Darling KEA, Babouee Flury B, Polli
 - 639 C, Sultan-Beyer L, Abela IA, Aebi-Popp K, the Swiss HIV Cohort Study. Brief Report: Does
 - Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?
 - JAIDS Journal of Acquired Immune Deficiency Syndromes. 2023;92(5):399-404.

- 642 61. Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen
- therapy on circulating inflammatory markers. Maturitas. 2009;62(3):281-6.
- 644 62. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, Furrer H, Schmid
- P, Bernasconi E, Stoeckle M, Kahlert C, Trkola A, Kouyos RD, Tarr P, Marzolini C, Wandeler G,
- 646 Fellay J, Bucher H, Yerly S, Suter F, Hirsch H, Huber M, Dollenmaier G, Perreau M, Martinetti
- 647 G, Rauch A, Günthard HF. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). Int J
- 648 Epidemiol. 2022;51(1):33-4j.

- 649 63. Olink Inflammation 2019 [Available from:
- 650 https://www.olink.com/content/uploads/2019/04/Olink-Inflammation-Validation-Data-v3.0.pdf.


medRxiv preprint doi: https://doi.org/10.1101/2023.05.09.23289654; this version posted May 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2023.05.09.23289654; this version posted May 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2023.05.09.23289654; this version posted May 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission. CW 40-60 Linear regression coefficient [95%CI] CW > 60 ■ TW 0.05 [0.01, 0.09] -0.02 [-0.04, 0.01] Effect of sex hormone on CD4 0.01 [-0.06, 0.08] 0.19 [0.1, 0.28] 0.03 [-0.01, 0.08] -0.03 [-0.06, 0] on CD8 0 [-0.08, 0.07] 0.08 [-0.01, 0.18] 0.01 [-0.02, 0.04] 0.01 [-0.01, 0.03] on CD4:CD8 ratio 0.01 [-0.04, 0.07] 0.08 [0.02, 0.15] 0.04 [-0.01, 0.09] -0.01 [-0.05, 0.02] on lymphocytes 0.09 [0, 0.18] 0.15 [0.04, 0.25]

-0.1

0

0.1

0.2

0.3

Figure 4

Marker

medRxiv preplitingar regression goofficient[95%&1]9.23289654; this version posted/with prayage 2220 Prayage Procession goofficient[95%&1]9.23289654; this version posted/with prayage 2220 Prayage Pr

